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TWO-DIGIT RESOLUTION TYPING OF CLASS-I HUMAN LEUKOCYTE ANTI-
GEN (HLA) DOES NOT COMPROMISE OUTCOMES IN ADULTS UNDERGO-
ING MATCHED UNRELATED ALLOGENEIC BONE MARROW
TRANSPLANTATION
Al Khabori, M.1, El-Emary, M.1, Messner, H.1, Lipton, J.1, Gupta, V.1,
Kuruvilla, J.1, denHollander, N.2, Tinckam, K.2, Buitron, N.1, Galal, A.1
1 Princess Margaret Hospital, Toronto, Canada; 2 University Health Net-
work, Toronto, Canada
HLA allelemismatchingmay be associated with inferior outcomes
in unrelated stem cell transplantation. Since July 2005, our trans-
plant unit performed 4-digit (allele level) HLA Class-I typing for
all unrelated donors from National Marrow Donor Program and
2-digit Class I typing was on all others. All donors had four-digit
Class-II typing. We reviewed all patients who received matched un-
related transplants (HLA-A, B, C, DR, and DQ) between July 2005
and February 2009. We compared overall survival and cumulative
incidences of relapse, acute and chronic graft versus host disease
(aGvHD, cGvHD) between the 4- and the 2-digit typing cohorts.
Themean age is 44.9 yrs for the 86 consecutive pts (17 and 69 respec-
tively). Most pts (61/86) have acute myeloid/lymphoid Leukemia or
myelodysplastic syndrome. Conditioning regimens included: BUCY
(Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, 5 pts), CY-
TBI (Cy 120 mg/kg, Total Body Irradiation 12 Grays, 21 pts),
Flu-Bu2 (Fludarabine 120 mg/m2, Bu 6.4 mg/kg, TBI 200 cGy, 38
pts), Flu-Bu4 (Flu 200 mg/m2, Bu 12.8 mg/kg, TBI 400 cGy, 19
pts) and Flu-Cy (Flu 120 mg/m2, Cy 40 mg/kg, 3 pts). Most grafts
are peripherally collected (68/86 pt) and most (63/86 pts) received
Alemtuzumab/CyA (Alemtuzumab 30 mg, Cyclosporine 5 mg/kg/
d) for GvHD prophylaxis. There are no statistically significant dif-
ferences between the baseline characteristics of the two groups
(age, sex, graft source, diagnosis, preparative regimen, GvHD pro-
phylaxis and CMV seropositivity). The median follow up is 25.3
months. Forty-two deaths occurred in both groups. The overall sur-
vival between the two groups is not statistically different (log rank
test, p5 0.58). There were 13 relapses with no statistically signifi-
cant difference in the cumulative rate of relapse between the two
groups, log-rank test p value5 0.91. Grade 2-4 aGvHD is seen in
52 pts and the cumulative rates are not different between the groups,
log-rank P value5 0.85. Thirty-three pts experienced limited or ex-
tensive cGvHD with no difference in the cumulative rates, log-rank
P value5 0.81. In a Cox model of overall survival using age, diagno-
sis, CMV seropositivity, GvHD prophylaxis, Conditioning regimen
and the level of matching; only diagnosis andCMV seropositivity are
statistically significant prognostic factors. In this single institution
retrospective study, 2-digit typing of HLA class-I is not associated
with inferior outcomes in matched unrelated transplantation.166
IS HLA MATCHING BY SBT A NECESSITY FOR BMT?
Chang, Y., Pascual, C.J., Alonzo, P. All Children’s Hospital, St. Peters-
burg, FL
Hematopoietic stem cell transplantation (HSCT) outcome has
improved dramatically since the introduction of allele level HLA
typing. Currently, HLA laboratories are using three different tech-
nologies for allele level matching, PCR amplification with se-
quence-specific primers (PCR-SSP), polymerase chain reaction-
sequence-specific oligonucleotide probes (SSOP), and sequence-
based typing (SBT). However, it is important to emphasize that
SBT is the only HLA typing method so far that allows scrutiny of ev-
ery nucleotide in the HLA gene sequence, therefore, it allows us to
recognize new alleles and potential gene mutations that would en-
sure allele level typing to be as good as claimed.
HLA high resolution typing was performed by SBT using Pro-
trans sequencing kits. Patient DNA samples were first PCR ampli-
fied by group-specific primer mixes to separate two HLA alleles.
The PCR products were then cycle-sequenced and processed on
an ABI 3100 genetic analyzer. Sequencing data were further analyzed
with the Assign 3.5 +HLA analysis software.
Our SBT data showed that the occurrence of new sequences in pa-
tients and donors is not negligible. We found it to be 3% in our local
ethnically diverse population, where a few patients even had two novel
sequences. Family analysis of sequencing data revealed that some se-
quence changes are actually HLA gene mutations that occur only inthe patient and are not found in the parents or siblings sharing the
same haplotype. By comparing patient peripheral blood samples with
buccal swabs, we confirmed that HLA gene mutations also occurred
in patient somatic cells. Had we used PCR-SSP or PCR-SSOP for
HLA typing these new alleles or mutations would have been missed.
We argue that spontaneous HLA gene mutations found in leuke-
mia or immunodeficiency patients that are not inherited fromparents
should not be reported as new alleles, unless the gene is known to be
passed on to the next generation that is healthy, or carried by at least
two normal individuals. If every mutation were reported as a new al-
lele, the already long lists of alleles would continue to increase, and
unnecessarily slow down the HLA matching process.
We speculate that HLA gene mutations might affect immune sur-
veillance and impact disease severity, because our patients with these
mutations had poor prognosis. Further study is required to clarify
the significance of HLA gene mutations.IMMUNE RECONSTITUTION
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FLT-3 LIGAND AND ANDROGEN WITHDRAWAL ENHANCE IMMUNE RE-
CONSTITUTION AFTER HSCT
Williams, K.M., Moore, A.R., Gress, R.E. National Cancer Institute,
NIH, Bethesda, MD
Impaired thymopoiesis contributes to immune deficiency following
HSCT.Clinical data suggest that thymic insufficiencymay contribute
to graft-versus-host disease and infectious clearance. We have previ-
ously shown that androgen withdrawal enhances thymus renewal by
thymic epithelial cell (TEC) proliferation, increased entry of thymic
progenitors and accelerated thymocyte development.Wenowdemon-
strate that FMS-like tyrosine kinase 3 (Flt-3) enhances thymopoiesis in
conjunction with androgen blockade. Flt-3 increases stem cell number
(LSK, Lineage- Sca-1+ cKit+), B cell precursors (Lineage- Sca-1 + IL-
7ra+), andT cell directed stemcells (Lineage- Sca-1+ cKit+CCR9+) in
the marrow of older mice without altering thymic function. Immature
granulocyte and dendritic cell precursors were also enriched in the
marrow. In contrast, in young mice, Flt-3 increased the emigration
of stem cells without altering the distribution of marrow cell popula-
tions. To test the effect of the Flt-3-treated marrow on thymic recon-
stitution, aged mice were pre-treated with lupron or saline and
conditioned with 900 cGy radiation. One million congenic T-cell de-
pleted marrow cells were adoptively transferred from Flt-3 treated or
saline treated donors. Flt-3-treated marrow in combination with lu-
pron led to themost rapid thymic reconstitution, nearly doubling total
congenic thymocytes by 5weeks post-transplant.Thymic subsetswere
increased including: CD4 single positive (2.67x), CD8 single positive
(2.69 x), double positive (1.92x), and double negative subsets (1.59x)
compared to saline-treatedmarrowand recipient controls.Thymocyte
subsets and total numbers were significantly greater in lupron-treated
hosts receiving Flt-3-treated marrow than in lupron-treated hosts re-
ceiving saline-treatedmarrow. Incontrast,Flt-3-treatedmarrowtrans-
ferred in the absence of lupron did not increase thymopoiesis. These
data suggest that: T cell directed precursor number and precursor en-
trymaybecritical points of thymic regulationpost-HSCT.Byenhanc-
ing TEC proliferation, T precursor emigration, and thymocyte
maturation via androgen withdrawal with lupron, it appears that pre-
cursor numberbecomes limiting. Flt-3 increasesTdirectedprecursors
in the marrow thereby further enhancing thymic recovery. These data
may present a clinical opportunity to improve thymic renewal follow-
ing stem cell transplantation by Flt-3 treatment of donors and andro-
gen withdrawal in hosts.168
IMMUNE RECONSTITUTION FOLLOWING REDUCED INTENSITY CONDI-
TIONING WITH CAMPATH-1H VERSUS TOTAL LYMPHOID IRRADIA-
TION/ANTI-THYMOCYTE GLOBULIN PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION
Glotzbecker, B.1, Mills, H.1, Rosenblatt, J.1, Wu, Z.2, Wellenstein, K.1,
Vasir, B.2, Joyce, R.1, Levine, J.1, Tzachanis, D.1, Zwicker, J.1,
Boussiotis, V.1, Stevenson, M.A.1, Spitzer, T.3, Delaney, C.1, Bonhoff, J.1,
Giallombardo, N.1, Conway, K.1, McDermott, D.1, Avigan, D.1 1 Beth Israel
Deaconess Medical Center, Boston, MA; 2Dana Farber Cancer Institute,
Boston, MA; 3 Massachusetts General Hospital, Boston, MA
S220 Poster Session IGraft versus host disease (GVHD) is a significant cause of morbid-
ity and mortality after allogeneic hematopoietic stem cell transplan-
tation. In vivo quantitative T-cell depletion using CAMPATH-1H
(anti-CD52) has been explored in an effort to prevent acute
GVHD. Recently, a regimen of total lymphoid irradiation (TLI)
and anti-thymocyte globulin (ATG) has been shown to polarize T-
cells towards an inhibitory phenotype potentially reducing the risk
for GVHD. However, these strategies may lead to impaired post-
transplant immune reconstitution, increased risk of tumor relapse
and opportunistic infection. We compared the immune recovery of
20 patients undergoing reduced intensity conditioning with low
dose CAMPATH and an initial cohort of 5 patients treated with
TLI/ATG. Conditioning with CAMPATH resulted in a significant
depletion of CD4 and CD8 T-cells in the early post-transplant pe-
riod and persistence of CD4 T-cell depletion for 6 months. Follow-
ing TLI/ATG, there was a persistent depletion of CD4 T-cells with
no significant decrease in CD8 T-cells. CAMPATH was associated
with a decrease in CD45RO+ memory T-cells in the early post-
transplant period (27.2 to 5.7%, p5 0.03). T-cell recovery in early
post-transplant following TLI/ATG was associated with a rise in
the relative percentages of naive T-cells (CD45RA+) (39 to 61.3%;
p5 0.04), central memory (CD45RO +CD62L +CCR7+) (CM)
(12 to 32.8%; p5 0.05), and a significant change in the central mem-
ory:effector memory (CD45RO +CD62L-CCR7-) (EM) ratio (0.2
to 1.0). The mean percentage of regulatory T-cells
(CD4 +CD25 + FoxP3+) rose in the early post-transplant period fol-
lowing both regimens (p\0.03). Functional analyses demonstrated
that the T-cell proliferative response to Phytohemagglutinin (PHA)
was profoundly depressed following CAMPATH with mean SI de-
creasing from 34 pre-transplant to 1.4 Day 30. Treatment with
TLI/ATG resulted in no significant change in response to PHA. As-
sessment of T-cell polarization after stimulation with PMA/ionomy-
cin, recipient derived dendritic cells (DCs) or third party DCs
demonstrated a rise of CD8 +T-cells expressing IL-4 and IL-10
consistent with a suppressor phenotype. In summary, both CAM-
PATH and TLI/ATG result in CD4 +T-cell depletion, but TLI/
ATG resulted in persistence of memory cells, relative preservation
of CM as compared to EM and intact response to mitogens. TLI/
ATG therapy was associated with a more modest level of functional
T-cell depletion characterized by Tc2 polarization.169
CD4 + CD25HIGHFOXP3 + REGULATORY T CELLS ARE INCREASED AND
FUNCTIONALLY ACTIVE AFTER ANTITHYMOCYTE GLOBULIN INFUSION
AND ALLOGENEIC STEM CELL TRANSPLANTATION IN HUMANS – A
NOVEL IN VIVO MECHANISM OF ACTION
Theurich, S.1, Reisberg, A.2, Christopeit, M.2, von Bergwelt-Baildon, M.1,
Weber, T.2, Riemann, D.3, Behre, G.2 1 University Hospital Cologne, Co-
logne, Germany; 2 University Hospital Halle, Halle (Saale), Germany;
3 University Hospital Halle, Halle (Saale), Germany
CD4 + CD25highFoxP3+ regulatory T cells (Tregs) play a central
role in immunologic homeostasis and are able to induce tolerance af-
ter allogeneic hematopoietic stem cell transplantation (alloPBSCT).
Polyclonal rabbit-anti-human antithymocyte globulins (rATG) are
widely used to prevent and treat Graft-versus-Host-Disease
(GvHD) after alloPBSCT. Their mechanism of action has been
thought to be mainly mediated by CD4+ effector T cell depletion
and complement-dependent lysis. Interestingly, recent in vitro data
have suggested that rATGs might increase the ratio or number of
regulatory T cells. But so far, it is not knownwhether such effects ex-
ist in humans in vivo.
Here, we present the data of a prospective pilot study in which we
analyzed the influence of rATGs on the reconstitution of peripheral
CD4+/CD25high/FoxP3 + Tregs after alloPBSCT.
Ten patients were divided into two groups depending on the re-
quirements of the respective alloPBSCT protocol: those who re-
ceived one type of rATG during conditioning therapy from day -3
to -1 (rATG; n5 6) and those who were conditioned without
rATG administration (non-rATG; n5 4). Patients of the rATG
group received a total dose of either rATG-Fresenius 30 mg/
kgBW (n5 3) or rATG-Genzyme 6 mg/kgBW (n5 3) respectively.
All patients received peripheral hematopoietic stem cells fromHLA-
matched donors and the grafts contained comparable median num-bers of CD3+ and CD34+ in both patient groups (table 1). GvHD
prophylaxis consisted of Mycophenolate Mofetil and Cyclosporine
A in all patients and antiviral prophylaxis was with acyclovir. Periph-
eral blood samples were taken before conditioning and after al-
loPBSCT at distinct time points (day +30, +60, +90 and +150) and
immune cells were analyzed by flow cytometry. An in vitro suppres-
sion assay of d + 150 Tregs from cryopreserved samples was done
with CD4 +CD25+ selected Tregs and CD4 +CD25- selected
CSFE labelled autologous responder T cells.
In summary, we found a more than 3-fold stable increase of rela-
tive Treg numbers in rATG treated patients after alloPBSCT com-
pared to the control. Day + 150 Tregs suppressed the responder cell
proliferation effectively in the in vitro assay.
Taken together, our results rise first evidence that rATG treat-
ment leads to increased, functional active CD4+/CD25high/
FoxP3 + Tregs in humans after allogeneic stem cell transplantation
which supports the thesis that rATG exhibit their immunomodula-
tory activity by additional mechanisms beyond simple cell depletion.
Table 1. Patient characteristics and transplantation parame-
ters
Baseline parameters rATG non-rATGPatients 6 4Age (median) 37 - 68 (61) 48 - 67 (62)Diagnosis MM, MCL, CLL, ALL AML (n5 3), OMFConditioning regimenRIC 5 3Standard 1 1Transplanted cell
numbers x 106/kg
BW recipient,
(median)CD341 PBSC 1.85 - 11.0 (7.6) 4.91 - 9.47 (7.3) p 0.47CD31 T cells 150 - 480 (219) 120 - 540 (175) p 0.38MRD: matched related donor; MUD: matched unrelated donor; RIC:
Reduced Intensity Conditioning (Treosulfan / Fludarabin or Cyclopho-
spamide/Fludarabin or 2 Gy-Total-Body-Irradiation/ Fludarabin); Stan-
dard conditioning (Cyclophosphamide/12 Gy-Total-Body-Irradiation).
BW: body weight; AML: acute myeloid leukaemia; OMF: osteomyelofib-
rosis; CLL: chronic lymphocytic leukaemia; ALL: acute lymphoblastic
leukaemia; MCL: mantle cell lymphoma; MM: multiple myeloma. PBSC:
peripheral blood stem cells. Cellular subpopulations of the transplanted
grafts were calculated to the respective recipients body weight. Statisti-
cal analysis by SPSS.170
ADOPTIVE TRANSFER OF EBV SPECIFIC T-CELLS FOR TREATMENT OF
PRIMARY AND RITUXAN RESISTANT EBV LYMPHOMAS FOLLOWING AL-
LOGENEIC STEM CELL TRANSPLANTS (HSCT): CLINICAL, VIRAL AND IM-
MUNOLOGIC CORELATES
Doubrovina, E., Oflaz-Sozmen, B., Kernan, N.A., Young, J.,
Abramson, S., Barker, J., Boulad, F., Castro-Malaspina, H., Teruya-
Feldstein, J., Filippa, D., Jakubowski, A., Papadopoulos, E.B.,
Prockop, S., Scaradavou, A., Small, T., O’Reilly, R.J. Memorial Sloan--
Kettering Cancer Center, New York, NY
EBV lymphomas (EBV-L) arising postHSCT that persist or recur
following Rituxan therapy are often fatal. We analyzed treatment
with EBV-specific T-cells (EBV-CTL) in 22 patients (pts) who de-
veloped EBV-L following HLA-matched (N5 8) or non-identical
N5 11 T cell depleted (N5 17) or unmodified (N5 3) HSCT or
cord blood grafts (N5 3). All pts had clinical and radiologic evidence
of rapidly growing tumors ofWaldeyer’s ring and/or intestines, liver,
lung or CNS and rising blood levels of EBV DNA. Biopsies showed
B cell, EBV+ lymphoma in 20 pts that were monoclonal (12/12
tested) and usually of donor origin (11/12 tested). Of 22 pts, 14
had failed (N5 10) or recurred (N5 4) following Rituxan treat-
ment. EBV-CTLwere grown from donorT-cells sensitized with au-
tologous EBVBLCL transformed by EBV strain B95.8 (B95.8
EBVBLCL) and tested for specificity, lack of alloreactivity and ste-
rility. Treatment included 3 weekly infusions of EBV-CTL (106 T
